CSL Current Ratio 1970-1969 | CSLLY

Current and historical current ratio for CSL (CSLLY) from 1970 to 1969. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. CSL current ratio for the three months ending December 31, 1969 was 0.00.
CSL Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $103.244B $10.310B
CSL Ltd. is a biopharmaceutical company. It engages in researches, develops, manufactures and markets vaccines and plasma protein biotherapies to treat and prevent human medical conditions. The company's operating segments consists of CSL Behring and bioCSL. CSL Behring segment provides plasma-derived and recombinant products, and operates plasma collection networks through CSL Plasma. bioCSL segment manufactures, sells and distributes vaccines, antivenoms and other pharmaceutical products primarily in Australia and New Zealand; as well as also manufactures and markets in vitro diagnostic products through Immunohaematology. It operates primarily in Germany, Switzerland and the United States. CSL Ltd. is headquartered in Parkville, Australia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.660B 8.90
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.482B 21.14
Biohaven Pharmaceutical Holding (BHVN) United States $8.764B 0.00
Emergent Biosolutions (EBS) United States $2.892B 6.98
Arcus Biosciences (RCUS) United States $2.573B 0.00
Myovant Sciences (MYOV) United Kingdom $2.051B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.021B 0.00
Zymeworks (ZYME) Canada $1.443B 0.00
Ambrx Biopharma (AMAM) United States $0.527B 0.00
SQZ Biotechnologies (SQZ) United States $0.417B 0.00
Enzo Biochem (ENZ) United States $0.172B 50.71